Last reviewed · How we verify

DiscGenics, Inc. — Portfolio Competitive Intelligence Brief

DiscGenics, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
IDCT (rebonuputemcel) IDCT (rebonuputemcel) phase 3 Cell therapy Orthopedics / Spine

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Biosolution Co., Ltd. · 1 shared drug class
  2. Bone Therapeutics S.A · 1 shared drug class
  3. Brainstorm-Cell Therapeutics · 1 shared drug class
  4. Celavie Bioscences, LLC · 1 shared drug class
  5. China Spinal Cord Injury Network · 1 shared drug class
  6. City of Hope Medical Center · 1 shared drug class
  7. Dr. Grant M. Pagdin · 1 shared drug class
  8. Avicenna Research Institute · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for DiscGenics, Inc.:

Cite this brief

Drug Landscape (2026). DiscGenics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/discgenics-inc. Accessed 2026-05-14.

Related